ArticleDrugs & aging2022
Onychomycosis in Older Adults: Prevalence, Diagnosis, and Management.
Article in Drugs & aging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 53 citations in OpenAlex.
- Trial
- Evaluation of safety and efficacy of calcipotriol 0.005% cream versus terbinafine hydrochloride 1% cream in treatment of onychomycosis; a randomized split body comparative pilot study.Archives of dermatological research · 2025Trial
- Trial
- Feet in Peril: Assessment of Feet in Patients Undergoing Haemodialysis.Journal of renal care · 2026Article
- Trends in antifungal use characteristics in primary care in Spain, 2019 to 2024: a nationwide study.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2026Observational
- Efficacy and Safety of Voriconazole for Difficult-to-Treat Distal Lateral Subungual Onychomycosis (DLSO).Pathogens (Basel, Switzerland) · 2025Article
- Enhanced Efinaconazole Permeation and Activity AgainstPharmaceutics · 2025Article
- Onychomycosis in special populations.Future microbiology · 2025Review
- The Spectrum of Non-dermatophyte Onychomycosis With Special Reference to Syncephalastrum as an Emerging Pathogen.Cureus · 2025Article
- Epidemiology and Trends of Cutaneous Fungal Infections (2019-2022) in Israel: A Single Tertiary-Center Study.Journal of fungi (Basel, Switzerland) · 2025Article
- Lipid-based nanoformulations in onychomycosis therapy: addressing challenges of current therapies and advancing treatment.RSC advances · 2025Review
- Analysis of Causative Factors and Potential Predictors of Onychomycosis: A Retrospective Single-Center Study in Poland.Journal of fungi (Basel, Switzerland) · 2025Article
- Structure-activity relationship studies of ME1111, a novel antifungal agent for topical treatment of onychomycosis.The Journal of antibiotics · 2025Article
- Ex Vivo Fungal Nail Penetration Study: Effects of Causative Organisms, Nail Polish and Age.Mycoses · 2025Article
- Nails in older adults.Annals of medicine · 2024Review
- Kerion-like lesions following an autoinoculation event in patient with chronic onychomycosis - Case report.Medical mycology case reports · 2024Article
- Aniline Derivatives Containing 1-Substituted 1,2,3-Triazole System as Potential Drug Candidates: Pharmacokinetic Profile Prediction, Lipophilicity Analysis Using Experimental and In Silico Studies.Pharmaceuticals (Basel, Switzerland) · 2024Article
- [Dermatomycoses: topical and systemic antifungal treatment].Dermatologie (Heidelberg, Germany) · 2024Review
- The prevalence of onychomycosis in patients with chronic renal failure undergoing dialysis: A cross-sectional study.Heliyon · 2024Article
- Gallic acid loaded self-nano emulsifying hydrogel-based drug delivery system against onychomycosis.Nanomedicine (London, England) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The risk of having onychomycosis increases with age. Data suggest that the prevalence of onychomycosis may be ≥ 20% in subjects aged ≥ 60 years and ≥ 50% in those aged ≥ 70 years. Older males are 2.1 times more prone to onychomycosis than are females. Although most nail dystrophies (approximately 50%) are caused by onychomycosis, proper clinical assessment followed by mycological examination is recommended to exclude other conditions such as nail trauma, lichen planus, and psoriasis. The US FDA-approved onychomycosis treatments are systemic antifungals (terbinafine and itraconazole) for severe onychomycosis and topical antifungals (ciclopirox 8%, efinaconazole 10%, and tavaborole 5%) for mild-to-moderate onychomycosis. Oral fluconazole is used off-label, and itraconazole may be considered for non-dermatophyte onychomycosis. Recently, fosravuconazole was approved in Japan for onychomycosis treatment. Although the treatment options and durations are the same for older patients as for other age groups, a clinical decision should take into account various age-related factors such as comorbidities, polypharmacy, hepatic and renal insufficiency, and noncompliance. Clinicians should also consider possible drug interactions and side effects when choosing a particular antifungal. Since the recurrence rate of onychomycosis is high, older patients should practice sanitization techniques, consider lifestyle changes, and perhaps consider using a topical antifungal as long-term maintenance therapy one to three times per week to prevent the recurrence of onychomycosis or to treat early disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.